Progress of cytokine release syndrome caused by chimeric antigen receptor T-cell immunotherapy
10.3760/cma.j.issn.1009-9921.2017.11.016
- VernacularTitle:嵌合抗原受体T细胞免疫疗法所致细胞因子释放综合征研究进展
- Author:
Yixin ZOU
1
Author Information
1. 210029,南京医科大学第一附属医院 江苏省人民医院血液科
- Keywords:
Chimeric antigen receptor T-cell;
Cytokine release syndrome;
Clinical manifestation
- From:
Journal of Leukemia & Lymphoma
2017;26(11):697-701
- CountryChina
- Language:Chinese
-
Abstract:
As a novel immune therapy for cancer, chimeric antigen receptor T-cell (CAR-T) immunotherapy has attracted more and more attention. Toxicities of CAR-T therapy include cytokine release syndrome (CRS), neurologic toxicities and on-target, off-tumor toxicity. CRS, which is the most severe adverse event of CAR-T immunotherapy, affects many organs, such as cardiovascular, nervous, digestive, hematological systems, and so on. Besides symptomatic treatment, tocilizumab (anti-interleukin monoclonal 6 antibody), etanercept (anti-tumor necrosis factor monoclonal antibody) and glucocorticoid are the core treatments to control CRS. Better understanding of CRS promotes the application of CAR-T immunotherapy.
